Dr. James Robl

Hematech, Founder Retired

Dr. Robl began his career as a professor at the University of Massachusetts in 1985.  In addition to his teaching efforts he conducted research on animal cloning and genetic engineering technologies.   In 1995 Dr. Robl became interested in the applications of embryo cloning and genetic engineering technologies and co-founded several biotechnology companies to pursue these applications.  In 2000, he left his position at the University of Massachusetts to become the president and chief scientific officer of Hematech, one of the companies he co-founded.  Under Dr. Robl’s leadership, Hematech grew to a company with 80 employees and capabilities for launching human therapeutics into clinical evaluation along with maintaining its status as a world leader in genetic engineering research.  Dr. Robl retired from Hematech in 2009 but still consults on occasion and retains his interest in science and the biotechnology industry.